Cochrane · systematic review · CD006945
Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Cheuk, DKL, Chiang, AKS, Chan, GCF, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Childhood CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
11
No studies
3
Included studies
NR
No studies 3 · 21.4%Ungraded 0 · 0%Very low 1 · 7.1%Low 10 · 71.4%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings: urate oxidase compared with allopurinol
Population: children with haematological malignancy at risk of tumour lysis syndrome
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of clinical tumour lysis syndrome ( Summary of findings: urate oxidase vs allopurinol | RR 0.77 [0.44, 1.33] | 1 study · 348 participants | Low Downgraded: risk of bias, imprecision |
Mortality due to tumour lysis syndrome ( Summary of findings: urate oxidase vs allopurinol | RR 0.05 [0, 0.89] | 3 studies · 396 participants | Low Downgraded: risk of bias, imprecision |
Renal failure requiring renal replacement therapy ( Summary of findings: urate oxidase vs allopurinol | RR 0.26 [0.08, 0.89] | 5 studies · 992 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Normalisation of serum uric acid Summary of findings: urate oxidase vs allopurinol | no estimate extracted | 1 study · 19 participants | Low Downgraded: risk of bias, imprecision |
Percentage reduction in serum uric acid level Summary of findings: urate oxidase vs allopurinol | no estimate extracted | NR | No studies |
AUC of serum uric acid level at 4 days ( Summary of findings: urate oxidase vs allopurinol | no estimate extracted | 1 study · 52 participants | Low Downgraded: risk of bias, imprecision |
Frequency of adverse events ( Summary of findings: urate oxidase vs allopurinol | RR 9.1 [1.29, 64] | 3 studies · 345 participants | Low Downgraded: risk of bias, imprecision |
Summary of findings: high‐dose urate oxidase compared with low‐dose urate oxidase
Population: children with haematological malignancy at risk of tumour lysis syndrome
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of clinical tumour lysis syndrome Summary of findings: high‐dose urate oxidase vs low‐dose urate oxidase | no estimate extracted | NR | No studies |
Mortality due to tumour lysis syndrome Summary of findings: high‐dose urate oxidase vs low‐dose urate oxidase | no estimate extracted | 1 study · 30 participants | Low Downgraded: risk of bias, imprecision |
Renal failure requiring renal replacement therapy Summary of findings: high‐dose urate oxidase vs low‐dose urate oxidase | no estimate extracted | 1 study · 29 participants | Low Downgraded: risk of bias, imprecision |
Normalisation of serum uric acid ( Summary of findings: high‐dose urate oxidase vs low‐dose urate oxidase | RR 1.07 [0.89, 1.28] | 1 study · 29 participants | Low Downgraded: risk of bias, imprecision |
Percentage reduction in serum uric acid level at 4 hours ( Summary of findings: high‐dose urate oxidase vs low‐dose urate oxidase | no estimate extracted | 1 study · 29 participants | Low Downgraded: risk of bias, imprecision |
AUC of serum uric acid level Summary of findings: high‐dose urate oxidase vs low‐dose urate oxidase | no estimate extracted | NR | No studies |
Frequency of adverse events ( Summary of findings: high‐dose urate oxidase vs low‐dose urate oxidase | RR 0.54 [0.12, 2.48] | 1 study · 29 participants | Low Downgraded: risk of bias, imprecision |